Study On Solid Lipid Nanoparticles Containing AAPA

Objective: To prepare spleen-targeting AAPA-loaded solid lipid nanoparticles using stearic acid, and investigate the in vitro and in vivo characteristics of nanoparticles. Rheumatism is a kind of chronic disease which injure the arthrosis and soft tissue of the patient, the clinical symptom is pain. Rheumatoidarthritis (RA) is a frequently encountered disease, the inflammation of RA mainly involve abarticulation, and inflammation often offends many different organs. At present, only a few medicines have excellent therapeutic effect on RA. As a result, the development of anti-RA drugs with excellent therapeutic effect and little side effects is a focus which was constantly paid close attention to 4 - Acetylaminophenylacetic acid (AAPA). AAPA is usually an orally administration active immunomodulator used in the treatment of rheumatoid arthritis. It has been documented that AAPA has a suppressive effect on the development of articular lesions in animals, and that it has prophylactic and therapeutic effects on inflammation in adjuvant arthritis in animals. One of the major problems entailed in using arises from its low solubility in water due to its extremely hydrophobic character. The commercial formulation of AAPA is only orally. In the present study we investigated the possibility of incorporating AAPA into solid lipid nanospheres (SLNs), colloidal therapeutic systems proposed for intravenous...